Also, the therapeutic potential of GLP-1 in preventing the adipocyte hyperplasia associated with obesity and in bolstering the maintenance of human mesenchymal stem cell (hMSC) stores by promoting the proliferation and cytoprotection of hMSC seems to be relevant. Since these observations suggest a role for GLP-1 during developmental processes, the aim of the present work was to characterize GLP-1 in early development as well as its gene targets in mouse embryonic stem (mES) cells. Mouse embryos E6, E8, and E10.5 and pluripotent mES were used for the inmunodetection of GLP-1 and GLP-1 receptor. Quantitative real-time PCR was used to determine the expression levels of GLP-1R in several tissues from E12.5 mouse embryos. Additionally, GLP-1 gene targets were studied in mES by multiple gene expression analyses. GLP-1 and its receptors were identified in mES and during embryonic development. In pluripotent mES, GLP-1 modified the expression of endodermal, ectodermal, and mesodermal gene markers as well as sonic hedgehog, noggin, members of the fibroblast and hepatic growth factor families, and others involved in pancreatic development. Additionally, GLP-1 promoted the expression of the antiapoptotic gene bcl2 and at the same time reduced proapoptotic caspase genes. Our results indicate that apart from the effects and therapeutic benefits of GLP-1 in adulthood, it may have additional gene targets in mES cells during embryonic life. Furthermore, the pathophysiological implications of GLP-1 imbalance in adulthood may have a counterpart during development. stem cells; mouse embryo; apoptosis; differentiation; proliferation GLUCAGON-LIKE PEPTIDE-1 (GLP-1) is encoded by the proglucagon gene, which is secreted by gut L cells and some brain neurons. It exerts multiple biological effects on peripheral tissues and on the central nervous system (1, 2, 10, 13). Thus, both GLP-1 and its analog exendin-4 stimulate glucose-dependent insulin secretion and have beneficial effects in the treatment of type 2 diabetes. It also acts as an anorexigenic peptide, reducing food intake, and hence, body weight (4, 18, 27). Interestingly, it causes the stimulation of pancreatic ␤-cell proliferation, the induction of islet neogenesis, and differentiation from exocrine cells or immature islet progenitors (7) and at the same time provides protection against ␤-cell apoptosis. In this sense, GLP-1 receptor (GLP-1R) knockout mice exhibit an abnormal islet size and islet topography (16) as well as an increased sensitivity to ␤-cell and neural cell injury, whereas other parameters such as feeding behavior and body weight lie within the normality in these mice (24). Moreover, GLP-1 promotes cellular proliferation and cytoprotection and prevents the differentiation of mesenchymal stem cells from human bone marrow [human mesenchymal stem cells (hMSC)] into adipocytes (23). These findings underscore the therapeutic potential of GLP-1 for preventing the adipocyte hyperplasia associated with obesity, and additionally, the peptide could bolster the maintenance of hMSC stores.
GLUCAGON-LIKE PEPTIDE-1 (GLP-1) is encoded by the proglucagon gene, which is secreted by gut L cells and some brain neurons. It exerts multiple biological effects on peripheral tissues and on the central nervous system (1, 2, 10, 13) . Thus, both GLP-1 and its analog exendin-4 stimulate glucose-dependent insulin secretion and have beneficial effects in the treatment of type 2 diabetes. It also acts as an anorexigenic peptide, reducing food intake, and hence, body weight (4, 18, 27) . Interestingly, it causes the stimulation of pancreatic ␤-cell proliferation, the induction of islet neogenesis, and differentiation from exocrine cells or immature islet progenitors (7) and at the same time provides protection against ␤-cell apoptosis. In this sense, GLP-1 receptor (GLP-1R) knockout mice exhibit an abnormal islet size and islet topography (16) as well as an increased sensitivity to ␤-cell and neural cell injury, whereas other parameters such as feeding behavior and body weight lie within the normality in these mice (24) . Moreover, GLP-1 promotes cellular proliferation and cytoprotection and prevents the differentiation of mesenchymal stem cells from human bone marrow [human mesenchymal stem cells (hMSC)] into adipocytes (23) . These findings underscore the therapeutic potential of GLP-1 for preventing the adipocyte hyperplasia associated with obesity, and additionally, the peptide could bolster the maintenance of hMSC stores.
Although the effects of GLP-1 have been studied previously, mainly in adult differentiated cells and also in embryonic stem (ES) cells, but to a lesser extent (3), our recent observations of the existence of its biological actions through GLP-1R in hMSC suggest that these processes or others may be induced by GLP-1 in pluripotent (ES) or embryonic cells. Embryonic development is a process that orchestrates many molecules by modulating processes such as proliferation, apoptosis, and differentiation in a time-dependent way. In this sense, embryonic stem cells with pluripotential capacity offer a useful model for the in vitro study of many molecular mechanisms that occur in vivo during embryonic development.
Thus, the main aim of this study was to characterize GLP-1 and its receptors as well as its gene targets in mouse embryonic stem (mES) cells in the early stages of mouse development.
MATERIALS AND METHODS
Mouse embryo collection. Female mice C57BL/6 were mated with males of the same strain to induce pregnancy. Noon on the day that vaginal plugs were observed was considered to be 0.5 days post coitum. Pregnant females were euthanized by cervical dislocation, and their staged embryos (26) were obtained from the uterus. The embryos were immediately placed in ice-cold 4% paraformaldehyde for processing by immunohistochemistry.
Cultured ES cells. Mouse ES cells (J1 line) (15) were maintained on mitotically inactive mouse embryonic fibroblasts in Dulbecco's modified Eagle's medium (BioWhittaker, Madrid, Spain) containing 15% heat-inactivated fetal bovine serum (FBS; HyClone), 2 mM L-glutamine, 0.1 mM nonessential amino acids (Chemicon), 100 mg/l streptomycin-penicillin (Biowhittaker), and 0.25 mM ␤-mercaptoethanol (Chemicon) and leukemia inhibitory factor (LIF; 1,000 U/ml, ESGRO; Chemicon). The culture medium was changed every day, and ES cells were passaged using 0.25% trypsin and reseeded on freshly prepared feeder layers.
Before analyses, trypsinized cells were allowed to attach to gelatincoated plates for 60 min, thus removing Ͼ95% of feeder cells and recovering Ͼ95% of mES cells. Then the mES cells recovered were plated on a nonadherent dish, and floating mES colonies were cultured in the same medium but with 0.1% FBS in the presence or absence of LIF and either GLP-1 (10 nM; Bachem) or blocking anti-GLP-1 (1 ng/l; Acris Antibodies) for 2 days. Both GLP-1 and the antibody were renewed each day.
Immunohistochemistry. Four mouse embryos per stage or mES were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 5 h or 30 min at 4°C. The embryos and mES were washed in PBS and processed for whole mount immunohistochemistry. Briefly, they were permeabilized with 0.4% Triton X-100 (PBS-T) for 30 min and blocked with PBS-T containing 10% normal goat serum (BioWhittaker) for 1 h. Cells were incubated overnight with primary antibodies in blocking solution at 4°C, washed three times with PBS, and then incubated with secondary antibodies in blocking solution for 2 h at room temperature. Finally, they were washed three times, and nuclei were stained with 1 g/ml 4,6-diamidino-2-phenylindole in PBS. The primary antibodies and dilutions were monoclonal mouse anti-GLP-1 1:100 (Acris Antibodies) and polyclonal rabbit anti-GLP-1R 1:50 (Acris Antibodies).
Fluorescence detection of GLP-1 and GLP-1R was performed by incubation with Alexa 488-conjugated goat anti-mouse antibody (Anaspec) and Texas Red-conjugated goat anti-rabbit antibody (Calbiochem) (both diluted 1:200 in blocking solution), respectively. The specificity of GLP-1 and GLP-1R immunodetection was confirmed by adding preimmune serum instead of primary antibody (data not shown). Images were taken with a TCS SP2 confocal laser microscopy system (Leica) equipped with an inverted DMIRE2 Leica microscope.
RNA extraction, cDNA transcription, and Southern blotting. Total RNA was isolated with the acid guanidinium isothiocyanate method (6) , and reverse transcription (RT) (Applied Biosystems, Foster City, CA) was performed with 1 g of total RNA to obtain 20 l of cDNA. Two microliters of cDNA was used as a template for PCR, following the manufacturer's instructions (Biotools B & M Laboratories, Madrid, Spain) and using the specific primers GLP-1R (5=-TCTCAGAGA-CAGTGCAGAAA-3= and 5=-CACGTGTAGATAATGTACAG-3=). To control the differences in initial RNA levels and tube-to-tube variations in PCR, a primer pair for 18S (5=-TCAAGAACGAAAGTCGGAGG-3= and 5=-GGACATCTAAGGG CATCACA-3=) was included in each PCR amplification. The conditions used were 94°C for 2 min, followed by 35 cycles at 94°C for 30 s, 58°C for 30 s, 72°C for 1 min, and a final extension cycle at 72°C for 10 min. In some cases, the analyses of RT-PCR products were performed with agarose gel electrophoresis and Southern blotting using a cDNA probe to GLP-1R labeled with digoxigenin by random priming, using the DIG DNA labeling kit from Boehringer Mannheim.
Multiple gene expression analyses in TaqMan Low-Density cards. RNA integrity was tested with the Bioanalyzer 2100 (Agilent), and cDNA synthesis was developed with the "high-capacity cDNA archive kit" (Applied Biosystems), using 500 ng of RNA as template in a final volume of 50 l, following the manufacturer's instructions.
Quantity real-time PCR was developed using the TaqMan Gene expression Master Mix (Applied Biosystems) on TaqMan Low-Density (TLDA) cards (Applied Biosystems). TLDA with 192 customized duplicated genes was used for the multiple gene expression analyses and analyzed with RQ Manager Software (Applied Biosystems). Five microliters of the cDNA synthesized was diluted in a final volume of 100 l and applied to each port of the TLDA card. PCR was developed in a 7900HT Fast Real-Time PCR System (Applied Biosystems). The conditions were 94.5°C for 10 min, followed by 40 cycles at 97°C for 30 s and 59.7°C for 1 min. Two housekeeping genes were used for the normalization procedure; these were 18S and GADPH. Median normalization was performed as follows: the median cycle threshold (C T) value of all genes on each TLDA card was subtracted from the CT value for each reaction well on that card such that after normalization the median CT value on each card was zero. The average 18S or GAPDH CT values on each TLDA card was then subtracted from the CT value for each reaction well on that card.
Western blot and immunodetection. mES cells were lysed in RIPA buffer (150 mM NaCl, 50 mM Tris·HCl, pH 7.2, 1% sodium deoxycholate, 1% Triton X-100, 0.25 mM EDTA, pH 8.0, 0.2% NaF, and 0.1% sodium orthovanadate) and a protease inhibitor cocktail tablet (Roche Diagnostics, Mannheim, Germany). Twenty micrograms of total proteins was separated by 10% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane (Millipore, Temecula, CA). The membrane was blocked with TBS containing 0.1% Tween 20 and 5% nonfat dried milk before incubation with the specific primary antibodies mouse anti-PCNA diluted 1:1,000, anti-Isl-1 1:3,000 (Millipore), and anti-Tuj-1 1:5,000 (Millipore). Loading controls were performed with a mouse anti-␤-actin antibody diluted to 1:5,000 (Sigma-Aldrich). Secondary antibodies conjugated with peroxidase were purchased from Bio-Rad (Richmond, CA). Bound proteins were visualized using chemiluminescent horseradish peroxidase substrate (Millipore).
RESULTS AND DISCUSSION
mES cells growing in standard culture medium expressed GLP-1R mRNA and protein in the case of both pluripotent cells (Pou5f1-positive, also named Oct-4) and those that had started to differentiate and had lost the expression of Pou5f1 (Fig. 1, A and B) . Mouse embryo fibroblasts did not express the GLP-1 receptor and thus were used as negative controls ( Fig. 2A, inset) . The levels of this mRNA receptor in ES cells were greater than those of insR and epidermal growth factor receptor (egfR), close to those of acvr2b and igf-IR, and lower than those of lifR and shh ( Fig. 2A) . In addition, GLP-1R/18S mRNA levels in tissues from embryonic day (E)12.5 mouse embryos were higher in lung, gut, head, and heart than in liver (Fig. 2B ). Both GLP-1 and its receptors were coexpressed in pluripotent or differentiating ES cells (Fig. 1B) and in mouse embryos as early as E6 of development in cylinder egg (mouse E6), in visceral endoderm,and in the future extraembryonic tissues (Fig. 2C) . In fact, GLP-1 promoted endodermal and tumor marker ␣-fetoprotein in pluripotent stem cells (Fig. 2D) , this being repressed by the blocking effect of GLP-1 antibodies. This suggests that the release of endogenous GLP-1 from such cells might favor cell differentiation up to endodermal lineages. The presence of GLP-1 and its receptors at an early stage of embryonic development, even before the appearance of the gut and cardiovascular system, suggests that this peptide may act by diffusion or through a paracrine pathway before an endocrine mechanism has been established. These findings suggest that the expression of the peptide and its receptor is not the consequence of cell differentiation but rather part of this process modulating key molecules in cellular differentiation, as also suggested by Bai et al. (3) , where the authors found that GLP-1 improves insulin production during in vitro differentiation of ES cells to insulin-producing cells.
GLP-1 and its receptors are present before the appearance of the gut and its specialized L cells as well as of pancreatic ␤-cells, indicating that its incretin effect is expressed later than other embryological phenomena. Furthermore, in adults GLP-1 is present in cells of endodermal origin and also in those derived from the ectoderm, such as hypothalamic neurons (1).
Our results indicate that both GLP-1 and its receptors are present in some cells of the neural ectoderm and surface ectoderm of the future forebrain in E8 mice (Fig. 3A) . The presence of GLP-1R in ectodermal cells, besides the already described endodermal ones, suggests a role for GLP-1 in ectoderm development. Thus, when mES cells were incubated with GLP-1, the peptide upregulated the expression of the ectodermal marker isl-1, also involved in pancreatic development, but was not able to modify the early neuroblast precursor tuj-1 (Fig. 3B) . By contrast, GLP-1 addition inhibited the neural stem cell marker nestin (Table 1) in mES. Additionally, endogenous GLP-1 acts by inhibiting nes gene since when anti-GLP-1 antibody was added to the mES the expression of nes genes increased 4.18 Ϯ 0.25-fold over the levels found in the presence of endogenous GLP-1.
In an attempt to determine the functions of GLP-1 in embryonic stem cells, we investigated the effect of GLP-1 under pluripotent (ϩLIF) conditions by the addition of 10 nM GLP-1 to cells over 2 days or by blocking the secreted endogenous GLP-1 with anti-GLP-1 antibody. Using proliferating cell nuclear antigen (PCNA) protein as a proliferation marker, our results indicated that although the addition of GLP-1 enhanced cell proliferation, with no modification in the expression of the pluripotency genes pou5f1 and nanog, the endogenous levels of GLP-1 were sufficient to maintain the self-renewal of mES cells. This was supported by the persisting PCNA levels and elevated pou5f1 and nanog expression when the cells were treated with anti-GLP-1 antibody (Fig. 4, A and B) . However, endogenous GLP-1 inhibited the pluripotent marker expression of genes such as pou5f1 and nanog. The actions of anti-GLP-1 were also exerted by the GLP-1R antagonist exendin 9 -39 (data not shown). GLP-1 significantly up-or downregulated several genes considered to be endodermal, mesodermal, and ectodermal markers, those involved in pancreatic development, such as the hepatocyte nuclear factor or fibroblast growth factor families, and apoptotic related genes (Table 1) . GLP-1 treatment induced the expression of antiapoptotic genes (bcl-2) and reduced the proapoptotic caspase family genes, activators (casp2, -8, and -9) and executioners (casp3 and -6) in undifferentiated pluripotent ES cells cultured for 2 days in the absence of serum (Table 1) . However, the inflammatory mediators of caspase family genes (casp1, -4, and -14) were GLP-1, glucagon-like peptide-1. Data represent the folds of increase or decrease of mRNA levels in mouse embryonic stem (mES) cells treated for 2 days with 10 nM GLP-1 relative to untreated cells. Genes with Ͼ10-fold variation are written in bold. Only statistically significant differences of genes involved in the indicated processes are shown. The data shown correspond to at least 2 independent experiments performed in duplicate.
induced by GLP-1 in undifferentiated ES. These results suggest that apoptotic activity is modified by GLP-1 in both adulthood and embryonic life, although the biological significance of this process may be of different relevance at both ages. Therefore, GLP-1 could act as a cytoprotector of pluripotent undifferentiated ES cells as well as of differentiated tissues, as described previously (8) .
Additionally, the presence of GLP-1 in mES facilitated or inhibited the expression of several genes involved in the differentiation of pancreatic ␤-cells, such as the egf and egfR genes, respectively (Table 1) . Thus, pancreatic islet development is impaired in mice lacking EGFRs (5), and even partial tissue-specific attenuation of EGFR signaling in the islets leads to marked reduction in ␤-cell proliferation and the development of diabetes during the first weeks after birth. Of the many EGFR ligands, betacellulin has been associated specifically with positive effects on ␤-cell growth (5) through both increased cell proliferation and neogenesis. According to in vitro models, EGFR is known to play a central role in the transdifferentiation of pancreatic acinar and ductal cells into endocrine islet cells.
GLP-1 and its receptors were also found at E10.5 in the somite lateral plate (Fig. 4C) , in the mesoderm boundary, and in the notochord area (Fig. 4D) , excluding the neural tube, where the sonic hedgehog plays an important role in the differentiation of the neural tube. Our results indicate that the GLP-1R and GLP-1 expression pattern skirting around the described Shh location in the neural tube of (Table 1) , one of the components located downstream from the Shh pathway. The effect of GLP-1 acting as a modulator of shh expression in pluripotent undifferentiated or differentiating cells suggests new functions for this peptide in embryonic morphogenesis. Sonic hedgehog is the best established example of a morphogen that exerts different effects on the cells of the developing embryo, depending on its concentration (20) . However, the Hedgehog (Hh) signaling pathway also plays an important role in adulthood because under normal conditions it is largely inactive in adult tissues (11, 22) and controls the cell division of adult stem cells. It has also been implicated in the development of some cancers when Hh signaling remains overactive.
Our results indicated that there were genes sensitive to the concentration of GLP-1. Thus, additional GLP-1 was necessary to upregulate the expression of egf, acvr2b, atf2, bmp6, crem, or dups2, with no apparent modifications when endogenous GLP-1 was removed ( Fig. 5A and Table 2 ). In contrast, other genes such as sox17 and brauchyury were very sensitive to endogenous GLP-1 elimination and were overexpressed Ͼ100-fold, whereas additional GLP-1 to a much lesser extent decreased the expression of these genes. Additionally, it seemed that endogenous GLP-1 inhibited the upregulation of these genes that occurred when the cells were induced to differentiate by deprivation of LIF (Fig. 5B and Table 2 ). Sox17 and Brauchyury are endodermal and mesodermal markers, respectively. Sox17 plays a role in endoderm formation, since Sox17-null embryos show a dramatic reduction in endodermal cell numbers. Its expression expands throughout the definitive endoderm in E7.5 and then rapidly disappears in the anterior endoderm, becoming restricted to the posterior (i.e., hindgut) endoderm (12) . Since the fore-, mid-, and hindgut endoderm are roughly generated in an anterior-to-posterior manner (9, 14, 25) , this anterior-to-posterior pattern of Sox17 expression may reflect its transient activation at the initial phase of definitive endoderm differentiation. In this regard, Sox17 modulation by GLP-1 could contribute to this differentiation pattern.
Others genes, including caspase or pluripotency genes, were also overexpressed when the actions of GLP-1 were blocked in mES cells (Fig. 6 and Table 2 ). Furthermore, it must be taken into account that GLP-1 has a short half-life due to the action of dipeptidylpeptidase IV (21) , but the dpp4 gene encoding that peptidase was decreased by GLP-1 itself (Ϫ7.33 Ϯ 0.6; Table  1 ) in mES cells, ensuring the functionality of this GLP-1. Additionally, control experiments using a more stable analog of GLP-1 (exendin 4) or the inhibitor of DPP-4, diprotin A, reproduced the results obtained with GLP-1 (data not shown). These results suggest that the balanced levels of that endoge- Comments should be made on how the phenotype of GLP-1R-null mice may be so little affected. These mice are viable, exhibit mild glucose intolerance, and present abnormal islet size and islet topography (24), but there was not any perturbation in organogenesis. However, the apparent shortage of defects should be due to compensatory mechamisms of other peptides even of the glucagon and related peptide families. Similar overlapping actions of several peptides together with GLP-1 in brain and peripheral tissues have also been well established, and consequently it would not be strange to surmise that these physiological actions would be expressed in GLP-1R-null mice. Thus, for example, it has been described that the elimination of GLP-1R signaling enhances the action of GLP-2 through the murine central nervous system (17) . Also, Pederson et al. (19) have described that GLP-1R Ϫ/Ϫ mice exhibit compensatory changes in the enteroinsular axis via increased glucose-dependent insulinotropic polypeptide (GIP) secretion and enhanced GIP actions. These lines of evidence are an example of compensatory mechanisms occurring in GLP-1R-null mice in adulthood. Therefore, although here we present evidence that GLP-1 is present and modulates key genes during embryonic development, it is not incompatible with the effects of many other compensatory peptides acting during embryonic development, as occurs in adult GLP-1R Ϫ/Ϫ mice. Similar mechanisms should be considered during the embryonic development of GLP-1R-null mice. In addition, it is well known that several peptides, including GLP-1, contribute to a biological effect and that the absence of one of them in null mice does not modify such biological effects.
Our findings indicate that GLP-1 has considerable plasticity with well-known actions in adulthood but also with other functions and gene targets in undifferentiated pluripotent cells during embryonic life. Depending on whether GLP-1 and its targets are located in embryonic or in adult tissues, this peptide may induce different effects or even act on the same processes, such as apoptosis. The results might be of different biological significance, depending not only on the period of life studied but also on the levels of this peptide at a given time. Although both GLP-1 and its receptors seem to appear at the same time early on in development, cells producing this peptide and the targets of its actions may differ between both ages. Likewise, the pathophysiological implications of GLP-1 in adulthood may have a counterpart during development.
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